Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDC looks at outpatient ADEs

Executive Summary

Adverse drug events resulted in an estimated 701,547 emergency room visits during each of the past two years, according to a federal study led by the CDC. One of every six of these ADEs required a subsequent hospital admission, transfer to another health care facility, or emergency department admission/observation, report Daniel Budnitz et al. in the Oct. 18 issue of JAMA. Among hospitalized patients, most ADEs were from unintentional overdoses, "and two-thirds of these were due to toxicity from a relatively small set of drugs for which regular monitoring is commonly required to prevent acute toxicity." Of the 18 drugs most commonly causing ADEs, 16 have been in use for more than 20 years. Insulins or warfarin were involved in one in seven of the ADEs treated in emergency departments. The CDC study is based on 2004 and 2005 data from the NEISS-CADES project, which is continuing to collect data on specific patient populations, drug classes, conditions and circumstances in an effort to identify measures to reduce outpatient ADEs...

You may also be interested in...



Medtronic Looks To Adaptive DBS To Advance Treatment Of Parkinson’s Disease

Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.

Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint

The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.

Regulatory Science Tools For Phantoms, Lab Methods Added To US FDA Catalog

The regulatory tools are for use in medical device development.

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel